AbbVie Backtracks on Huge Price Hike for Cancer Drug
Against a backdrop of widespread scrutiny of drug prices, Pharmacyclics opted to scrap a plan to triple the price of its blood cancer drug, Imbruvica (ibrutinib).
Source: Drug Industry Daily
Against a backdrop of widespread scrutiny of drug prices, Pharmacyclics opted to scrap a plan to triple the price of its blood cancer drug, Imbruvica (ibrutinib).
Source: Drug Industry Daily